Related Experiment Video
Updated: Jan 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dofetilide in atrial fibrillation: A comprehensive review
Diksha Mahendru1, Harin D Joshi2, Peter Kowey3
1Division of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.
Insights
Dofetilide effectively controls atrial fibrillation (AF) rhythm by selectively blocking a potassium current. While safe for heart patients, its use requires careful monitoring due to potential side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with substantial global health impact.
- Managing AF involves complex strategies including rate/rhythm control, anticoagulation, and comorbidity management.
Purpose of the Study:
- To provide a comprehensive review of dofetilide, a Class III antiarrhythmic agent.
- To analyze dofetilide's pharmacology, clinical evidence, safety, and guideline recommendations.
Main Methods:
- Literature review of dofetilide's properties and clinical applications.
- Analysis of clinical trial data and safety profiles.
- Examination of guideline recommendations and special population considerations.
Main Results:
- Dofetilide selectively blocks the IKr potassium current, offering rhythm control with minimal negative inotropy.
- Its safety profile is favorable for patients with structural heart disease and left ventricular dysfunction.
- Concerns include torsades de pointes risk, requiring in-hospital initiation and strict monitoring.
Conclusions:
- Dofetilide is a valuable option for AF rhythm control, particularly in specific patient groups.
- Careful patient selection and monitoring are crucial for safe and effective use.
- Further research and real-world data are needed to optimize its application.
Abstract:
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with significant morbidity, mortality, and healthcare burden worldwide. The management of AF remains complex, encompassing rate and rhythm control strategies, anticoagulation, and comorbidity optimization. Dofetilide, a class III antiarrhythmic agent, has emerged as an important therapeutic option for rhythm control due to its relatively selective blockade of the rapid component of the delayed rectifier potassium current (IKr). Unlike many other antiarrhythmics, it lacks significant negative inotropy, making it safe for use in patients with structural heart disease and left ventricular dysfunction. However, its use is limited by concerns regarding torsades de pointes, mandatory in-hospital initiation, and stringent monitoring requirements. This review provides a comprehensive analysis of dofetilide, including its pharmacology, clinical trial evidence, safety profile, guideline recommendations, role in special populations, real-world application in India, and future perspectives.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias I: Introduction

